Cure My Disease

Don't miss your cure!

 Log in / Sign up

Leftover urine may predict bladder cancer recurrence

NCT ID NCT04617743

Knowledge-focused Sponsor: Istanbul Medeniyet University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time

Summary

This study investigates whether the amount of urine left in the bladder after urination (post-void residual) influences the return or worsening of non-muscle invasive bladder cancer. Researchers will follow 500 patients who have had surgery to remove bladder tumors, measuring residual urine and tracking cancer recurrence and progression over time. The goal is to see if higher residual urine volume is linked to higher recurrence rates.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If a link is found, doctors might use residual urine measurements to better predict and monitor recurrence risk in bladder cancer patients.
What could go wrong
This is an observational study, so it cannot prove cause and effect. The results may not change current treatment or monitoring practices.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

500 people

The number who actually took part.

Started

Nov 2020

Finished

Nov 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with transitional cell non-muscle invasive bladder cancer pathology and patients with follow-up data

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with transitional cell non-muscle invasive bladder cancer (NMIBC) pathology * Patients with a diagnosis of Bladder cancer (NMIBC) * Patients undergoing transurethral resection for bladder cancer (NMIBC) * ≥18 years old patients Exclusion Criteria: * Non-transitional cell bladder cancers * Patients with muscle-invasive bladder cancer pathology * \<18 years old patients

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bladder cancer recurrent are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Disease Progression non-invasive bladder urothelial carcinoma Non-Muscle Invasive Bladder Neoplasms Recurrence urinary bladder cancer urinary bladder carcinoma Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bladder cancer recurrent Non-invasive bladder urothelial carcinoma

Contacts and locations

Locations

  • Health Sciences University, Dıskapi Yildirim Beyazit Training and Research Hospital

    Ankara, Turkey (Türkiye)

  • Health Sciences University, Tepecik Training and Research Hospital

    Izmir, Turkey (Türkiye)

  • Istanbul Medeniyet University

    Istanbul, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.